Risk of Post Transfusion Hepatitis C Virus Infection

Status Completed

Clinical Trial Summary

To determine the risk of transfusion-transmitted hepatitis C virus (HCV) in cardiac surgery patients before and after donor screening for anti-HCV and surrogate markers of non-A, non-B hepatitis (NANBH). Also, to characterize donors who were HCV seronegative and who lacked surrogate markers at the time of donation, but whose recipient seroconverted to HCV.

Clinical Trial Description

BACKGROUND:

In the early 1990s, posttransfusion NANBH, mainly caused by HCV, was the most common serious complication of transfusions, occurring in 2-5 percent of transfusion recipients. About 50 percent of those infected developed chronic hepatitis, of whom, 10 to 20 percent developed cirrhosis. Hepatocellular carcinoma had been reported to occur in some. This study provided the first evaluation of the effectiveness of donor screening for anti-HCV by the then recently licensed HCV antibody test and surrogate markers of NANBH. It also provided a precise estimate of the risk of transfusion-transmitted HCV. The results allowed examination of risk factors for HCV infected donors who were seronegative at the time of donation.

DESIGN NARRATIVE:

The study was a nonconcurrent prospective, seroepidemiologic study. To estimate the incidence of HCV infection, six-month postoperative serum samples were tested for antibody to HCV. Preoperative samples corresponding to positive postoperative sera were also tested. The donors of a patient who received blood screened for HCV, i.e., a donation since May, 1990, and seroconverted in the six months since transfusion were located and retested for antibodies to HCV. The donors were administered a questionnaire designed to ascertain risk factors for HCV infection. A sample of donors who were HCV positive at the time of donation were given the same questionnaire. Comparison of these three groups of donors (i.e., seropositives, donors tested negative but implicated in seroconversion, seronegatives) allowed an investigation of factors associated with false negative screening results. Analytical methods included standard methods for contingency tables and both conditional and unconditional logistic regression.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00005339
Study type	Observational
Source	National Heart, Lung, and Blood Institute (NHLBI)
Contact
Status	Completed
Phase	N/A
Start date	February 1992
Completion date	April 2004

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03651154` - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections	N/A
Completed	`NCT01136590` - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery	Phase 4
Completed	`NCT00097006` - Retrovirus Epidemiology Donor Study-II (REDS-II)	N/A
Completed	`NCT00005303` - Effectiveness of AIDS Antibody Screening	N/A
Completed	`NCT00005319` - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine	N/A
Completed	`NCT00005301` - Transfusion Safety Study (TSS)	N/A
Completed	`NCT00000581` - Granulocyte Transfusion Study	Phase 3
Completed	`NCT04089865` - Oral Versus Intravenous Tranexamic Acid	Phase 4
Completed	`NCT02968654` - TRansfusion Strategies in Acute Brain INjured Patients	N/A
Enrolling by invitation	`NCT06019364` - Transfusion of Whole Blood in Acute Bleeding
Completed	`NCT04911413` - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery	Phase 4
Completed	`NCT03727230` - RhD+ Blood Transfusion to Asian-type DEL Recipients	N/A
Recruiting	`NCT06102590` - Oxygen Extraction-guided Transfusion	N/A
Completed	`NCT00400192` - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury	N/A
Completed	`NCT00000593` - Viral Activation Transfusion Study (VATS)	N/A
Completed	`NCT05627544` - Blood Transfusion Applications in Hip Replacements
Completed	`NCT05581238` - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Not yet recruiting	`NCT03429790` - Cell Salvage During Caesarean Section (CSCS)	N/A
Completed	`NCT00822588` - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not	N/A
Withdrawn	`NCT00269971` - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.